What compounds target IRAK4?

BiohacksAI has identified 35 compounds that interact with IRAK4 (interleukin 1 receptor associated kinase 4). Top compounds include: gefitinib, alvocidib, tozasertib, vandetanib, ponatinib. Each compound is ranked by evidence score derived from PubMed bioassay confidence and assay count.

What is IRAK4 (interleukin 1 receptor)?

IRAK4 is interleukin 1 receptor associated kinase 4. It is a molecular target for 35 compounds documented in PubMed bioassay data. NCBI Gene ID: 51135.

IRAK4

MOLECULAR TARGET

interleukin 1 receptor associated kinase 4

NCBI Gene: 5113535 compounds

IRAK4 (interleukin 1 receptor associated kinase 4) is targeted by 35 compounds in the BiohacksAI evidence corpus, derived from PubMed bioassay data. Each compound is ranked by confidence score (log-normalized assay count × evidence quality).

Compounds Targeting IRAK4

Ranked by bioassay confidence score (PubChem active assay count × evidence quality).

#	Compound	Confidence	Active Assays
1	gefitinib	5.67	290
2	alvocidib	4.52	91
3	tozasertib	4.33	75
4	vandetanib	4.30	73
5	ponatinib	4.26	70
6	bosutinib	4.08	58
7	bi 2536	4.01	54
8	quizartinib	3.99	53
9	nintedanib	3.61	36
10	canertinib	3.53	33
11	tae 684	3.43	30
12	fedratinib	3.40	29
13	gilteritinib	3.40	29
14	dovitinib	3.09	21
15	lestaurtinib	3.04	20
16	r 406	2.83	16
17	k 252a	2.83	16
18	milciclib	2.77	15
19	pf 00562271	2.77	15
20	pha 665752	2.71	14
21	crenolanib	2.71	14
22	kw 2449	2.64	13
23	azd 7762	2.30	9
24	su 014813	2.20	8
25	rebastinib	2.20	8
26	cyc 116	2.08	7
27	mk 2461	2.08	7
28	whi p131	1.95	6
29	pf 03814735	1.79	5
30	ucn 01	1.79	5
31	zimlovisertib	1.79	5
32	Dasatinib	0.69	1
33	sp600125	0.69	1
34	bdb chembl3401984	0.69	1
35	bdb chembl3401987	0.69	1

About IRAK4 as a Drug Target

IRAK4 (interleukin 1 receptor associated kinase 4) is a well-characterized molecular target in biomedical research. BiohacksAI tracks 35 compounds with documented IRAK4 interaction from PubChem bioassay data, cross-referenced with PubMed clinical evidence. The confidence score reflects the log-normalized count of active PubChem assays, weighted by evidence quality from the BiohacksAI corpus.

IRAK4 inhibitors, activators, and modulators are of interest in research areas including longevity, metabolic health, and neurological function. Each compound profile includes evidence score, RCT count, human study ratio, research velocity, and domain relevance.